← Back to Home

A New Test in Breast Cancer Liver Metastases: HEPZATO Enters Phase 2 Human Dosing

Delcath is moving its localized chemotherapy platform, already used in liver-dominant ocular melanoma, into metastatic breast cancer dominated by liver lesions; dosing the first participant is a starting point, not a conclusion about efficacy.

By SURL BioNews

The hardest part of metastatic breast cancer often lies not only in the tumor having left its primary site, but in the distinct biological and treatment challenges posed by lesions in different organs. When the disease is mainly pressing on the liver, physicians face the question of whether, beyond systemic therapy, they can more directly address the tumor burden within the liver. Delcath Systems announced that HEPZATO has completed dosing of the first patient in a Phase 2 clinical trial for liver-dominant metastatic breast cancer, moving this liver-directed therapy into testing in a new tumor category.

According to information released by the company and republished by BioSpace, the trial is targeting patients with metastatic breast cancer in which liver lesions are dominant. In clinical development, “first patient dosed” means the trial has truly begun generating human data, but it remains an early milestone; no conclusions about efficacy, safety, or whether the data may eventually be sufficient to support indication expansion can currently be inferred from this news.

The core concept of HEPZATO is to deliver a cytotoxic chemotherapy drug such as melphalan to the area where lesions are located through a liver-directed approach, seeking to increase intrahepatic exposure while reducing systemic exposure. This strategy differs from the targeted therapies, immunotherapies, or antibody-drug conjugates commonly seen in breast cancer drug development in recent years. It is not looking for a new molecular target, but redesigning the route by which an older chemotherapy drug reaches the tumor.

This is also why the case deserves a closer read in breast cancer. Treatment for metastatic breast cancer has become increasingly segmented by hormone receptor status, HER2 status, genetic alterations, and prior treatment history; but for patients whose liver lesions are clearly dominant, local organ burden may still influence symptoms, liver function, and the room available for subsequent therapy. If HEPZATO is to find a place here, it will need to demonstrate not only intrahepatic responses on imaging, but also whether patients can tolerate the procedure and drug-related risks.

The limitations are equally clear. The publicly available details in this news remain limited, with no interpretable data yet on response rate, progression-free survival, quality of life, or adverse events; Phase 2 trials also usually remain exploratory in nature and can be affected by participant characteristics, prior treatments, and control of extrahepatic disease. For patients, it does not constitute clinical guidance; for research and development, the real questions will only emerge after more participants and follow-up data are available.

HEPZATO was previously approved in the United States for a specific population of adults with uveal melanoma liver metastases, giving Delcath a platform foundation that can be tested for extension. Now that it has entered a breast cancer liver metastasis trial, the focus is not on naturally extrapolating an existing approval, but on whether the same liver-directed delivery logic can find measurable clinical value in a more common cancer type with more complex treatment options.

References

  1. BioSpace